HB0043

Phase 2Small molecule

SShanghai Huaota Biopharmaceutical Co., Ltd.

HB0043 is one of 71 small molecule programs targeting Hidradenitis Suppurativa. It is currently in Phase 2.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[3][1]

Indication

Hidradenitis SuppurativaRecruiting

Efficacy and SafetyNot yet recruiting

Hidradenitis SuppurativaPhase 2

Recruiting

Efficacy and SafetyPhase 2

Not yet recruiting

Competition

Competitive Landscape

228 competitors in Efficacy and Safety

#DrugCompanyPhaseTrials

Rinvoq

AbbVie

Phase 3

4 2

Savaysa

Daiichi Sankyo

Phase 3

3 3

Platinol

MMcNeil Consumer & Specialty Pharmaceuticals, a Division of McNeil-PPC, Inc.

Phase 3

7 4

Rapamune

PPrism Pharmaceuticals

Phase 3

5 5

Rilutek

AAzurity Pharmaceuticals

Phase 3

3 6

Kineret

SSwedish Orphan Biovitrum

Phase 3

2 7

UPLIZNA

HHorizon Therapeutics Ireland DAC

Phase 3

1 8

Apatinib Mesylate

BBukwang Pharmaceutical

Phase 3

1 9

Becotatug Vedotin

FFudan University

Phase 3

1 10

Raphamin

MMateria Medica Holding

Phase 3

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Q1 2027

Phase 1/2Not yet recruiting

Efficacy and Safety

NCT07449156

Clinical

Trials by Indication[1]

Efficacy and Safety1 trial

A Study to Evaluate Efficacy and Safety of HB0043 in Aadult Patients With Moderate to Severe Acne Vulgaris.

Not yet recruiting·SShanghai Huaota Biopharmaceutical Co., Ltd.·Phase 1/2·NCT07449156·21 enrolled

Hidradenitis Suppurativa1 trial

Efficacy, Safety, and Tolerability of HB0043 in Hidradenitis Suppurativa Patients.

Recruiting·SShanghai Huaota Biopharmaceutical Co., Ltd.·Phase 1/2·NCT06895499·15 enrolled

Adult1 trial

A Study to Evaluate Single-dose of HB0043 in Healthy Adult Participants

Recruiting·SShanghai Huaota Biopharmaceutical Co., Ltd.·Phase 1·NCT06999083·52 enrolled

Sources

References

[1]
ClinicalTrials.gov — 3 trial records for HB0043. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — HB0043 compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for HB0043. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — Shanghai Huaota Biopharmaceutical Co., Ltd. company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Phase 2[1]
Company: SShanghai Huaota Biopharmaceutical Co., Ltd.

HB0043

Status by Indication[3][1]

Competitive Landscape

Expected Milestones

Q1 2027

Trials by Indication[1]

Efficacy and Safety1 trial

Hidradenitis Suppurativa1 trial

Adult1 trial

References

Drug Info

Quick Facts

Related News